Home / Europe / Romania / Life Sciences & Healthcare

Life Sciences & Healthcare

We work with and have established long-term relationships with the top 100 lifesciences companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our lifesciences teams in Central and Eastern Europe advise leading global business groups in the sector on transactions, commercial agreements, compliance, investigations and litigation, very often across multiple jurisdictions in the region and beyond. We can help you to navigate the regulatory landscape and to ensure compliance with both local laws and global policies.

With over 480 international specialist lawyers across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your lifesciences business. Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics.

With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice.


Feed

02/12/2024
How to achieve a European Patent Office technical effect in mathematical...
More light is shed on how to achieve a European Patent Office technical effect in mathematical healthcare patents in a recent Board of Appeal case.A patent using maths on blood sample data survived opposition...
28/11/2024
CMS’s insights on COP29 themes
The discussions at COP29 Azerbaijan show how difficult it is to achieve global environmental goals. CMS lawyers have been reflecting on the themes of the conference in short videos and articles, housed...
18/11/2024
EU cybersecurity agency opens consultation on draft NIS2 guidance
On 7 November 2024, the EU Agency for Cybersecurity (ENISA) published for industry consultation the draft implementing guidance to support relevant entities to implement technical and methodological requirements...
12/11/2024
AI in healthcare inventions - uncertainty relating to processing medical...
European Patent Office (EPO) Board of Appeal decision T 1741/22 has cast doubt on the circumstances of when a mathematical method may be considered to contribute to technical character in the processing...
07/11/2024
A clinical trial protocol as a pointer to the claimed crystalline form...
In recent decision T 1152/21, the Board of Appeal finds that a phase I and phase II clinical trial protocol provided a pointer to the claimed crystalline form of a compound, despite the lack of any trial...
04/10/2024
Cannabis law and legislation in Romania
Medical use Law no. 339/2005 (the Law) provides that the growth, import and sale of cannabis for medical use is allowed in Romania, but under strict Government supervision. Patients may be prescribed...
24/09/2024
Priority entitlement: the EPO implements the new “rebuttable pre­sump­tion”...
In recent Technical Board of Appeal decision T 2360/19, the Board considered the validity of priority claims following the Enlarged Board of Appeal consolidated decision G 1/22 and G 2/22.The opposed...
09/08/2024
Antibody Appeals Uncovered
Since the first approval of Muromonab-CD3 in 1986, antibodies have become progressively more common, frequently reaching a ‘block­buster’ status. According to statistics provided by Statista in March...
25/07/2024
EU anti-dumping investigations of Chinese glyoxylic acid imports
On 25 July 2024, the EU opened an anti-dumping in­vest­ig­a­tion con­cern­ing EU imports of glyoxylic acid originating in the People’s Republic of China, which could lead to substantial anti-dumping duties...
19/07/2024
A healthy balance between novelty and sufficiency for a claimed therapeutic...
The question of novelty and sufficiency of second medical use claims in light of clinical trial prior art has been addressed by the EPO Boards of Appeal on a number of occasions. In recent decision T...
26/06/2024
Updated CMS Expert Guide to Cannabis law and legislation
CMS Expert Guide on cannabis law and legislation gives stakeholders detailed and updated information on the latest developments in cannabis regulation in key markets.  The Guide now covers 33 jurisdictions...
13/06/2024
What’s in a name? The use of a product code in a clinical trial protocol...
The use of product or sponsor codes in clinical trial related documents is common practice in the pharmaceutical space. However, such codes may not always be sufficient to disregard a publication as relevant...